Is mirtazapine 15 mg nightly safe and appropriate for a 74‑year‑old patient with chronic obstructive pulmonary disease (COPD) who is using bilevel positive airway pressure (BiPAP)?

Mirtazapine 15 mg Nightly in a 74-Year-Old with COPD on BiPAP: Safety Assessment

Mirtazapine 15 mg nightly is generally safe for this patient, though recent high-quality evidence shows it does not improve breathlessness in COPD and may cause adverse reactions. The FDA-approved starting dose of 15 mg is appropriate, but careful monitoring for respiratory depression and sedation is essential given the concurrent BiPAP use 1.

Key Safety Considerations

Respiratory Effects

The primary concern is mirtazapine's potential impact on respiratory function in a patient already requiring BiPAP support:

• Mirtazapine does not significantly worsen respiratory parameters in COPD patients. The largest randomized controlled trial (BETTER-B, 2024) involving 225 COPD and ILD patients found no significant differences in respiratory adverse events between mirtazapine (up to 45 mg) and placebo 2.

• However, sedation is a notable side effect that could theoretically impair respiratory drive. The FDA label specifically notes somnolence as a prominent effect due to H1-receptor antagonism 1. In a patient on BiPAP, excessive sedation could reduce spontaneous respiratory effort.

• BiPAP itself may interact with sedating medications. While guidelines support BiPAP use in chronic stable hypercapnic COPD 3, adding sedating agents requires vigilance for worsening hypercapnia or reduced ventilatory response.

Evidence on Efficacy and Safety

The BETTER-B trial (2024) provides the most definitive evidence 2:

• No improvement in worst breathlessness scores at 56 days (difference 0.105, p=0.69)
• 64% of mirtazapine patients experienced adverse reactions vs. 40% on placebo
• Mortality at day 56: 3 deaths (mirtazapine) vs. 2 deaths (placebo)
• Conclusion: Mirtazapine does not improve severe breathlessness and may cause adverse reactions

This contradicts earlier promising case series 4 but represents higher-quality evidence that should guide practice.

Specific Risks in This Population

Age-related pharmacokinetic changes are critical 1:

• Oral clearance reduced by 40% in elderly males compared to younger males
• Elimination half-life ranges 20-40 hours, longer in females (37 hours vs. 26 hours in males)
• The 74-year-old patient will have prolonged drug exposure, increasing sedation risk

Cardiac considerations 1:

• At 75 mg (1.67× maximum dose), mirtazapine does not prolong QTc to a clinically meaningful extent
• At the prescribed 15 mg dose, cardiac risk is minimal
• However, monitor for orthostatic hypotension due to α1-adrenergic receptor antagonism

Drug Interactions and Monitoring

No major respiratory contraindications exist 5:

• Unlike beta-blockers, which should be avoided in COPD 5, mirtazapine has no direct bronchoconstrictive effects
• The AHA palliative care guideline notes mirtazapine is safe in cardiovascular disease, though efficacy for depression in CVD is unproven 6

Monitor for 1:

• Excessive sedation or confusion (may indicate need for dose reduction)
• Worsening hypercapnia on blood gas analysis
• Falls risk (sedation + orthostatic hypotension)
• Weight gain and increased appetite (may be beneficial if patient is malnourished)

Clinical Recommendation Algorithm

If prescribed for depression/anxiety/insomnia:

1. Continue 15 mg nightly as this is the FDA-approved starting dose 1
2. Assess after 1-2 weeks for sedation, confusion, or worsening respiratory status
3. Check BiPAP compliance and efficacy to ensure adequate ventilatory support
4. Consider dose reduction if excessive sedation occurs, though this is off-label
5. Do not increase dose beyond 15 mg without clear benefit, given BETTER-B findings 2

If prescribed specifically for breathlessness:

1. Reconsider this indication given BETTER-B trial results showing no benefit 2
2. Explore alternative palliative approaches per AHA guidelines: low-dose opioids (morphine 2.5 mg), fans, pulmonary rehabilitation 6
3. If continuing mirtazapine for other indications (depression, insomnia, appetite), the 15 mg dose remains reasonable

Common Pitfalls to Avoid

• Do not assume mirtazapine will improve breathlessness based on older case series 4; the 2024 RCT definitively shows no benefit 2
• Do not overlook sedation risk in elderly patients on BiPAP—this combination requires closer monitoring than either intervention alone
• Do not abruptly discontinue if stopping is needed; taper gradually to avoid withdrawal symptoms 1
• Do not use mirtazapine as a respiratory stimulant—unlike doxapram, it has no role in acute respiratory failure 5

Bottom Line

Mirtazapine 15 mg nightly is acceptably safe in this 74-year-old with COPD on BiPAP, provided it is prescribed for appropriate indications (depression, anxiety, insomnia, or appetite stimulation) and not for breathlessness relief. Close monitoring for sedation and respiratory status is mandatory. The recent BETTER-B trial 2 definitively shows mirtazapine does not improve breathlessness in COPD, so if this is the primary indication, alternative palliative strategies should be pursued 6.